On Tuesday, Shares of EMC Corporation (NYSE:EMC), lost -1.97% to $26.42.
WANdisco (WAND.L), declared the release of WANdisco Fusion™ 2.6 with new features only accessible to customers who purchase WANdisco Fusion Enterprise Edition for Hadoop ®.
These new WAN administration capabilities combine with WANdisco Fusion’s patented active-active replication technology, which delivers always-on availability, performance and scalability across Hadoop clusters any distance apart, enabling the most stringent SLAs to be met. At the same time, they eliminate the need for expensive “bump-in-the-wire” network optimization hardware and software that can add hundreds of thousands of dollars of cost with noteworthy complexity. These cost savings will be on top of the major hardware cost savings WANdisco Fusion brings to Hadoop deployments.
“WANdisco Fusion’s features are critical for enterprises looking to scale-up large Hadoop deployments,” said David Richards, WANdisco CEO and Co-Founder. “Customers tell us they are seeing noteworthyROI, with savings in hardware costs alone on the order of 50%. And while ease-of-use generally isn’t the first thing that comes to mind when one thinks about big data, WANdisco Fusion simplifies the Hadoop experience in a way that is truly unique in this space.”
WANdisco Fusion offers a flexible, easy-to-deploy architecture that can be implemented across mixed storage environments, counting Oracle BDA, Cloudera, Hortonworks (HDP), EMC (EMC) and MapR. With all platforms, the functionality is the same.
EMC Corporation develops, delivers, and supports information infrastructure and virtual infrastructure technologies, solutions, and services. It offers enterprise storage systems and software deployed in storage area networks (SAN), networked attached storage (NAS), unified storage combining NAS and SAN, object storage, and/or direct attached storage environments, in addition to provides a portfolio of backup products that support a range of enterprise application workloads.
Finally, Novavax, Inc (NASDAQ:NVAX), ended its last trade with -4.60% loss, and closed at $13.49.
Novavax, Inc, declared its financial results for the second quarter and six months ended June 30, 2015.
Financial Results for the Three and Six Months Ended June 30, 2015
Novavax stated a net loss of $20.6 million, or $0.08 per share, for the second quarter of 2015, contrast to a net loss of $17.9 million, or $0.08 per share, for the second quarter of 2014. For the six months ended June 30, 2015, the net loss was $45.0 million, or $0.18 per share, contrast to a net loss of $31.7 million, or $0.15 per share, for the same period in 2014.
Novavax revenue in the second quarter of 2015 raised 69% to $14.0 million, contrast to $8.3 million for the same period in 2014. This enhance results from the recovery of additional costs under the HHS BARDA contract for the settlement of indirect rates for fiscal years 2011 and 2012, resulting in an additional $7.7 million in revenue for the quarter. This enhance in revenue was partially offset by a decrease in revenue resulting from a lower level of development activities under the HHS BARDA contract and our PATH agreement in the second quarter of 2015 as contrast to the same period in 2014.
The cost of government contracts revenue in the second quarter of 2015 reduced 47% to $2.7 million, contrast to $5.1 million for the same period in 2014. The decrease in cost of government contracts revenue was associated with a lower level of development activities under the HHS BARDA contract in the second quarter of 2015 as contrast to the same period in 2014.
Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
